Core Insights - The company reported a revenue of 3.751 billion yuan for the first half of 2025, with a net profit attributable to shareholders of 163 million yuan, indicating a focus on innovation and transformation into a pharmaceutical enterprise [1] Group 1: Financial Performance - The company's revenue, adjusted for the two-invoice system, was 4.374 billion yuan, with a net profit of 177 million yuan after excluding non-recurring gains and losses [1] - Brand business revenue reached 2.716 billion yuan, a year-on-year increase of 1.36%, accounting for 72.41% of total revenue [2] - The gross profit from brand business was 1.286 billion yuan, with a gross profit margin of 93.99%, making it the primary source of profit for the company [2] Group 2: Brand Performance - The "global calcium supplement expert" Dikao brand generated 905 million yuan in revenue, maintaining its position as the top imported calcium supplement brand in China for nine consecutive years [3] - The "first brand in anti-liver fibrosis" Fuzheng Huayu achieved revenue of 371 million yuan, a year-on-year growth of 37.42%, indicating a growing market potential [3] - The company is actively expanding its online channels to drive brand growth and optimize product structure, with a focus on high-margin products [3] Group 3: Innovation and Strategic Investments - The company is accelerating its transformation into an innovative pharmaceutical enterprise, driven by national innovation strategies and a focus on clinical value [4] - Significant investments have been made in innovative products, including partnerships with ZAP Surgical and Huahao Zhongtian, to commercialize advanced medical technologies in China [4][5] - The company has initiated promotional activities for its innovative drug Yutidelong, covering over 500 hospitals nationwide, and is advancing multiple clinical research projects [5]

Core Viewpoint - Baiyang Pharmaceutical is focusing on innovation and transformation into an innovative pharmaceutical company, with significant growth in brand operations and strategic investments in high-value innovative products [1][4][5]. Financial Performance - In the first half of 2025, Baiyang Pharmaceutical reported revenue of 3.751 billion yuan, which increases to 4.374 billion yuan when excluding the two-invoice system business. The net profit attributable to shareholders was 163 million yuan, with a net profit of 177 million yuan after excluding non-recurring gains and losses [1]. Brand Operations - The brand operation business generated revenue of 2.716 billion yuan in the first half of 2025, a year-on-year increase of 1.36%, accounting for 72.41% of total revenue. In Q2, revenue reached 1.421 billion yuan, a quarter-on-quarter increase of 9.75%. When adjusted for the two-invoice system, brand revenue was 3.339 billion yuan, up 14.91% year-on-year [2]. - Key brands include: - "Dijiao," with revenue of 905 million yuan, maintaining the top position in the domestic imported calcium supplement market for nine consecutive years. - "Fuzheng Huayu," with revenue of 371 million yuan, showing a year-on-year growth of 37.42%. - "NutriSumma," with revenue of 78 million yuan, up 34.83% year-on-year. - "Hailu," with revenue of 376 million yuan, a year-on-year increase of 14.86% [2]. Product Structure Optimization - Baiyang Pharmaceutical has successfully optimized its product structure, with the revenue share of exclusive patented products continuously increasing. The rapid growth of high-margin products has contributed to the overall increase in gross profit [3]. Innovation and Strategic Investments - The company is leveraging national innovation strategies to drive transformation in the pharmaceutical industry, focusing on clinical value and innovation as core growth engines. Baiyang is transitioning from a commercialization platform to an innovative pharmaceutical enterprise through a dual approach of "investment incubation + commercialization" [4]. - Recent strategic investments include: - ZAP Surgical, gaining commercialization rights for the ZAP-X Mars surgical robot in China. - Huahao Zhongtian, securing commercialization rights for a new generation of microtubule inhibitors. - Beihai Kangcheng, obtaining rights for specific rare disease products in mainland China and Hong Kong [4]. Progress in Innovation Projects - Baiyang Pharmaceutical has made substantial progress in various innovative projects, including: - The promotion of the drug Yutidelong, which has reached over 500 hospitals nationwide. - The first anti-drug-resistant tuberculosis drug NTB-3119M is undergoing Phase I clinical trials. - The innovative nuclear medicine drug 99mTc-3PRGD2 has been prioritized for review. - The global first innovative drug RAB001 for treating bone necrosis is in Phase II clinical trials [5].

Core Viewpoint - Baiyang Pharmaceutical is focusing on transforming into an innovative pharmaceutical company, with significant investments in innovative drugs and devices, as evidenced by its financial performance in the first half of 2025 [2][3] Financial Performance - In the first half of 2025, Baiyang Pharmaceutical reported revenue of 3.751 billion yuan, which increases to 4.374 billion yuan when excluding the two-invoice system business [2] - The net profit attributable to shareholders was 163 million yuan, with a net profit of 177 million yuan after excluding non-recurring gains and losses [2] - The brand operation business achieved revenue of 2.716 billion yuan, a year-on-year increase of 1.36%, accounting for 72.41% of total revenue [2] - When excluding the two-invoice system, brand business revenue reached 3.339 billion yuan, reflecting a year-on-year growth of 14.91% [2] - The gross profit from brand business was 1.286 billion yuan, with a gross profit margin of 93.99%, making it the main source of profit for the company [2] Strategic Initiatives - Baiyang Pharmaceutical is accelerating the introduction of new products and investment in innovation to create a second growth curve [3] - The company has strategically invested in global leaders in radiation therapy, innovative pharmaceuticals, and rare diseases, acquiring commercial rights to several innovative products [3] - Key innovative projects include the anti-drug-resistant tuberculosis drug NTB-3119M, which is in Phase I clinical trials, and the innovative nuclear medicine drug 99mTc-3PRGD2, which has been prioritized for review [3] - The globally pioneering innovative drug RAB001 for treating bone necrosis is currently undergoing Phase II clinical trials [3]

智通财经APP讯，百洋医药(301015.SZ)发布2025年半年度报告，该公司营业收入为37.51亿元，同比减 少6.02%。归属于上市公司股东的净利润为1.63亿元，同比减少59.48%。归属于上市公司股东的扣除非 经常性损益的净利润为1.77亿元，同比减少52.16%。基本每股收益为0.31元。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月28日，百洋医药发布公告称，2025年上半年实现营业 收入37.51亿元，同比下降6.02%；归属于上市公司股东的净利润为1.63亿元，同比下降59.48%；归属于 上市公司股东的扣除非经常性损益的净利润为1.77亿元，同比下降52.16%。 ...

青岛百洋医药股份有限公司 董事会议事规则 第一条 为了进一步规范青岛百洋医药股份有限公司（以下简称"公司"） 董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事 会规范运作和科学决策水平，根据《中华人民共和国公司法》等有关法律、行政 法规、规范性文件和《青岛百洋医药股份有限公司章程》（以下简称"《公司章 程》"），公司制定本议事规则。 第二条 公司证券部负责处理董事会日常事务。 公司董事会秘书兼任证券部负责人，保管董事会印章。 第三条 董事会会议分为定期会议和临时会议。 董事会每年应当至少在上下两个半年度各召开一次定期会议。 第四条 在发出召开董事会定期会议的通知前，证券部应当充分征求各董事 的意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总经理和其他高级管理人员的意见。 董事长、被征求意见的董事、总经理和其他高级管理人员对内幕信息应当严 格履行保密义务。 第五条 有下列情形之一的，董事会应当召开临时会议： 第六条 按照前条规定提议召开董事会临时会议的，应当通过证券部或者直 接向董事长提交经提议人签字（盖章）的书面提议。书面提议中应当载明下列事 项： 1 （一） ...

青岛百洋医药股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 第一章 总则 第一条 为加强青岛百洋医药股份有限公司（以下简称"公司"）董事和高 级管理人员所持本公司股份及其变动的管理，维护证券市场秩序，根据《中华人 民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司董事和高级管理人员所持本公司股份及其变 动管理规则》《深圳证券交易所上市公司自律监管指引第10号——股份变动管理》 等有关法律、行政法规、规范性文件和《青岛百洋医药股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，结合公司实际情况，公司制定本制度。 第二条 本制度适用于公司董事和高级管理人员，其所持本公司股份是指登 记在其名下和利用他人账户持有的所有本公司股份。公司董事和高级管理人员从 事融资融券交易的，其所持本公司股份还包括记载在其信用账户内的本公司股份， 公司董事和高级管理人员不得从事以公司股票为标的证券的融资融券交易。 公司董事和高级管理人员就其所持股份变动相关事项作出承诺的，应当严格 遵守。 第三条 本公司董事和高级管理人员在买卖公司股票及其衍生品种前，应知 悉《 ...

青岛百洋医药股份有限公司 投资者关系工作管理制度 第一章 总则 第一条 为加强对青岛百洋医药股份有限公司（以下简称"公司"）投资者 关系工作的管理，完善公司治理结构，切实保护投资者特别是社会公众投资者的 合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》《上市公司投资者关系管理工作指引》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、行政法 规、规范性文件和《青岛百洋医药股份有限公司章程》（以下简称"《公司章程》"）， 公司制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理工作的基本原则是： （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内 部规章制度，以及行业普遍遵守的道德规范和行为准则。 （二）平等性原则。 ...

青岛百洋医药股份有限公司 独立董事工作制度 第一章 总则 第一条 为规范独立董事行为，充分发挥独立董事在青岛百洋医药股份有限 公司（以下简称"公司"）治理中的作用，促进提高公司质量，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司独立董事管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2号——创业板上市公司规范运作》等有关法律、行政法规、规范性文件和《青 岛百洋医药股份有限公司章程》（以下简称"《公司章程》"），公司建立独立 董事制度，并制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主 要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交 易所业务规则和《公司章程》的要求，认真履行职责，在董事会中发挥参与决策、 监督制衡、专业咨询作用，维护公司整体利益，保护中小 ...

青岛百洋医药股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范青岛百洋医药股份有限公司（以下简称"公司"）选聘会计 师事务所行为，提升审计质量，维护公司和全体股东的合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规 则》《国有企业、上市公司选聘会计师事务所管理办法》等有关法律、行政法规、 规范性文件，结合公司实际情况，公司制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。 公司聘任会计师事务所从事除财务会计报告审计之外的其他法定审计业务 的，可以视重要性程度参照本制度执行。 第三条 公司选聘会计师事务所，应当由审计委员会审议同意后，提交董事 会审议，并由股东会决定。公司不得在董事会审议、股东会决定前聘请会计师事 务所开展任何业务。 第四条 公司股东、实际控制人不得在公司董事会审议、股东会决定前，向 公司指定会计师事务所，也不得干预审计委员会独立履行审核职责。 第二章 会计师事务所执业质量要求 第五条 公司选聘的会计师事务所应当具备下列条件： （一）具有独立 ...